T
Tourmaline Bio
Developing transformative medicines that dramatically improve the lives of patients with life-altering immune diseases
About Tourmaline Bio
Tourmaline Bio is a biotechnology company focused on developing transformative medicines aimed at dramatically improving the lives of patients with life-altering immune diseases. The company operates in the biopharmaceutical market, targeting rare and significant unmet medical needs. Tourmaline Bio serves patients suffering from severe immune disorders, working closely with healthcare providers and research institutions. Their business model revolves around the research, development, and commercialization of innovative therapies. Revenue is generated through the successful development and approval of these therapies, followed by their commercialization either directly or through partnerships with larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2023
Open roles
Tourmaline Bio in the New York City ecosystem
The Tourmaline Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- QLQVT Financial LP
Hydra Ventures- PEPetrichor
Series A3 investors entered at this stage
TCGX
Deep Track Capital- CICowen Healthcare Investments
Series B and later10 investors entered at this stage
- PBParadigm BioCapital
RA Capital Management- GPGreat Point Partners
- APAcuta Capital Partners
- QUQiming Venture Partners USA
- BRBraidwell
- AAAffinity Asset Advisors
- SCStemPoint Capital
- KCKVP Capital
Vivo Capital
Source: Dealroom Talent Intelligence.
Patents
6 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Tourmaline Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Novartis acquires Tourmaline (October 2025)